Another company entering a study in this area.  It seems they have aspirations to enter not only mCRPC but also have something in pre-clinical for Triple Negative Breast Cancer - similar to Zenith plans.  It seems that their PCM-075 drug is targeting PLK1 enzyme. 

http://trovagene.investorroom.com/2017-12-14-Trovagene-Submits-Protocol-to-FDA-for-Phase-2-Clinical-Trial-of-PCM-075-in-Combination-with-Zytiga-R-for-Metastatic-Castration-Resistant-Prostate-Cancer 

TrovaGene (TROV) said Thursday it has filed the protocol for a phase 2 study of PCM-075 in combination with Johnson & Johnson's (JNJ) Zytiga for metastatic castration-resistant prostate cancer for review by the US Food and Drug Administration.

The company said the primary efficacy endpoint is the proportion of patients achieving disease control after 12 weeks of study treatment, as defined by lack of prostate specific antigen progression in patients who are showing signs of early progressive disease while currently receiving androgen deprivation therapy plus abiraterone and prednisone.

If the FDA allows the study to proceed, Trovagene plans to start it in 2018.

----------------

masila